BRAHMS CgA II KRYPTOR
Device
Brahms GmbH
Total Payments
$49,674
Transactions
11
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $915.11 | 3 | 0 |
| 2022 | $48,759 | 8 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $49,674 | 11 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Chromogranin A as Surveillance biomarker in Patients with cARcinoids - the CASPAR study | Brahms GmbH | $48,759 | 0 |
| CASPAR-study Reference Range study for chromogranin A and copeptin proAVP | Brahms GmbH | $915.11 | 0 |
Top Doctors Receiving Payments for BRAHMS CgA II KRYPTOR
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Palo Alto, CA | $49,674 | 11 |
Ad
Manufacturing Companies
- Brahms GmbH $49,674
Product Information
- Type Device
- Total Payments $49,674
- Total Doctors 0
- Transactions 11
About BRAHMS CgA II KRYPTOR
BRAHMS CgA II KRYPTOR is a device associated with $49,674 in payments to 0 healthcare providers, recorded across 11 transactions in the CMS Open Payments database. The primary manufacturer is Brahms GmbH.
Payment data is available from 2022 to 2023. In 2023, $915.11 was paid across 3 transactions to 0 doctors.
The most common payment nature for BRAHMS CgA II KRYPTOR is "Unspecified" ($49,674, 100.0% of total).
BRAHMS CgA II KRYPTOR is associated with 2 research studies, including "Chromogranin A as Surveillance biomarker in Patients with cARcinoids - the CASPAR study" ($48,759).